Pharmacosmos A/S

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pharmacosmos A/S sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 3 currently recruiting 7 completed later-stage tilt top decile by trial count

Pharmacosmos A/S: 10 sponsored US clinical trials, 3 recruiting.

Pharmacosmos A/S sponsors 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 7 completed. 9 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Iron Deficiency Anaemia, with 2 trials.

Top-decile sponsor footprint

Pharmacosmos A/S ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 3

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

NCT07473128
RECRUITING Phase 3

Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

NCT06929806
RECRUITING Phase 3

Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

NCT05179226
COMPLETED Phase 3

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03237065
COMPLETED Phase 3

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03238911
COMPLETED Phase 3

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

NCT02962648
COMPLETED Phase 3

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

NCT02940860
COMPLETED Phase 3

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02940886
COMPLETED Phase 3

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

NCT02130063
COMPLETED Phase 1

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

NCT01280240

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 9

Therapeutic Areas

Iron Deficiency Anaemia 2
Iron Deficiency Anemia 2
Iron Deficiencies 1
Iron Deficiency, Anaemia in Children 1
Chronic Heart Failure 1

Where Pharmacosmos A/S enrollment is open (later-stage tilt)

3 recruiting of 10 indexed (30% open); 7 completed (70%).

Phase mix: 9 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Iron Deficiency Anaemia (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pharmacosmos A/S: open-pipeline peers nationwide

Peers matched on 10 registered trials and 30% open enrollment, not the therapeutic-area sidebar.

Pharmacosmos A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 9.99.91010.1 0%10%20%30%40% Total trials Recruiting share Pharmacosmos A/SAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsCentre hospitalier de l'Université de Montréal (CHUM)Child TrendsJacques E. ChellyJason Sperry
Pharmacosmos A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pharmacosmos A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 30% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Pharmacosmos A/S page

10 registered trials is a research-attention snapshot, not an endorsement of Pharmacosmos A/S or any single study.

  • 3 of Pharmacosmos A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Iron Deficiency Anaemia is the condition Pharmacosmos A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Iron Deficiency Anaemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pharmacosmos A/S pipeline card: 10 registered trials from official public datasets.Report a data error.